- Roche Holding AG (OTC:RHHBY) reported core earnings per share (EPS) of CHF 19.46 (approximately $25.40 USD), reflecting an 11% increase at constant exchange rates (CER) from the prior year. This came in slightly below some analyst expectations but supported a positive financial outlook for 2026, with the company targeting high single-digit growth in core EPS at CER. The company's revenue (group sales) for full-year 2025 was CHF 61.5 billion (approximately $80 billion USD). This represented strong underlying performance, with sales up 7% at CER.
- Roche projects a mid single-digit increase in group sales for 2026 and plans to further increase its dividend, supported by a healthy debt-to-equity ratio of 1.21 and a current ratio of 1.29.
Roche Holding AG, trading under the symbol OTC:RHHBY, is a leading Swiss pharmaceutical company known for its innovative drug pipeline and diagnostic solutions. Competing with pharmaceutical giants like Novartis and Pfizer, Roche's strong market position is reflected in its financial metrics, such as a price-to-earnings (P/E) ratio of 46.89 and a price-to-sales ratio of 5.72.
On January 29, 2026, Roche reported core EPS growth aligned with its strong operational results. This performance supports the company's optimistic forecast for 2026, which anticipates high single-digit growth in core EPS, assuming constant currency conditions. The company's robust drug pipeline is expected to drive this growth, as highlighted by its recent financial outlook. Roche's revenue for the full-year period was CHF 61.5 billion (approximately $80 billion USD), reflecting solid sales growth driven by its pharmaceuticals division. This performance is supported by the company's strong sales growth in 2025, where group sales increased by 7% at constant exchange rates. The Pharmaceuticals Division, in particular, saw a 9% rise in sales (to CHF 47.7 billion), driven by demand for key products like Phesgo, Xolair, and Ocrevus.In the fourth quarter of 2025, Roche's sales increased by 8%, showcasing continued positive momentum.
The company's core operating profit rose by 13%, supported by higher sales and efficiency improvements. This strong operational performance contributed to a 58% surge in IFRS net income, benefiting from the base effect of impairment charges in 2024. Looking ahead, Roche projects a mid single-digit increase in group sales for 2026, with plans to further increase its dividend in Swiss francs. The company's financial health is underscored by a debt-to-equity ratio of 1.21 and a current ratio of 1.29, indicating its ability to manage debt and cover short-term liabilities effectively.
